Patents by Inventor Jolanta Grembecka

Jolanta Grembecka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 11883381
    Abstract: Provided herein are small molecule inhibitors of ASH1L activity and small molecules that facilitate ASH1L degradation and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 30, 2024
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, David Rogawski, Dmitry Borkin, Szymon Klossowski, Zhuang Jin, Deanna Montgomery, Jing Deng, Marta Krotoska, Hao Li
  • GAS41 inhibitors and methods of use thereof
    Patent number: 11858925
    Abstract: Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: January 2, 2024
    Assignee: The Regents of the University of Michigan
    Inventors: Alyssa Winkler, Brian Linhares, Dymytrii Listunov, Jolanta Grembecka, Tomasz Cierpicki, EunGi Kim
  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 11833210
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: December 5, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11786602
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: October 17, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • Substituted inhibitors of menin-MLL and methods of use
    Patent number: 11673898
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins with compositions of Formula (II-A). The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions of Formula (II-A) for use in these methods are also provided.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 13, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11633490
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: April 25, 2023
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20230118233
    Abstract: Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.
    Type: Application
    Filed: April 28, 2022
    Publication date: April 20, 2023
    Inventors: Tomasz Cierpicki, Jolanta Grembecka, Weijiang Ying, Yiwu Yao, Felicia Gray, Qingjie Zhao
  • NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20230046569
    Abstract: Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.
    Type: Application
    Filed: April 26, 2022
    Publication date: February 16, 2023
    Inventors: Tomasz Cierpicki, Jolanta Grembecka, Huang Huang, Sergei Zari, Hyo Je Cho, Mykhaylo Potopnyk, Sergii Dudkin, Wenbing Chen, Yassir Adam, Christina Howard, EunGi Kim
  • Bridged bicyclic inhibitors of menin-MLL and methods of use
    Patent number: 11555041
    Abstract: The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: January 17, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin
  • Methods and compositions for inhibiting the interaction of menin with MLL proteins
    Patent number: 11542248
    Abstract: The present disclosure provides compositions and methods of use to inhibit the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compositions and methods of use are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 3, 2023
    Assignees: KURA ONCOLOGY, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu, Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock
  • ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH
    Publication number: 20220288217
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Application
    Filed: October 18, 2021
    Publication date: September 15, 2022
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • NSD family inhibitors and methods of treatment therewith
    Patent number: 11324729
    Abstract: Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: May 10, 2022
    Inventors: Tomasz Cierpicki, Jolanta Grembecka, Huang Huang, Sergei Zari, Hyo Je Cho, Mykhaylo Potopnyk, Sergii Dudkin, Wenbing Chen, Yassir Adam, Christina Howard, EunGi Kim
  • PRC1 inhibitors and methods of treatment therewith
    Patent number: 11319302
    Abstract: Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 3, 2022
    Assignee: The Regents of the University of Michigan
    Inventors: Tomasz Cierpicki, Jolanta Grembecka, Weijiang Ying, Yiwu Yao, Felicia Gray, Qingjie Zhao
  • ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT
    Publication number: 20220072142
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Application
    Filed: September 7, 2021
    Publication date: March 10, 2022
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • GAS41 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220017509
    Abstract: Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.
    Type: Application
    Filed: January 27, 2021
    Publication date: January 20, 2022
    Inventors: Alyssa Winkler, Brian Linhares, Dymytrii Listunov, Jolanta Grembecka, Tomasz Cierpicki, EunGi Kim
  • ASH1L inhibitors and methods of treatment therewith
    Patent number: 11147885
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: October 19, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • ASH1L degraders and methods of treatment therewith
    Patent number: 11110177
    Abstract: Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 7, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim, Dong Chen
  • BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE
    Publication number: 20210107917
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
    Type: Application
    Filed: July 13, 2020
    Publication date: April 15, 2021
    Inventors: Tao WU, Liansheng LI, Yi WANG, Pingda REN, Jolanta GREMBECKA, Tomasz CIERPICKI, Szymon KLOSSOWSKI, Jonathan POLLOCK, Dmitry BORKIN
  • SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE
    Publication number: 20210101908
    Abstract: The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
    Type: Application
    Filed: July 30, 2020
    Publication date: April 8, 2021
    Inventors: Tao WU, Liansheng LI, Yi WANG, Pingda REN, Jolanta GREMBECKA, Tomasz CIERPICKI, Szymon KLOSSOWSKI, Jonathan POLLOCK, Dmitry BORKIN
  • Thienopyrimidine and thienopyridine compounds and methods of use thereof
    Patent number: RE49687
    Abstract: The present disclosure provides compounds and methods for inhibiting the interaction of menin with its upstream or downstream signaling molecules including but not limited to MLL1, MLL2 and MLL-fusion oncoproteins. Compounds of the disclosure may be used in methods for the treatment of a wide variety of cancers and other diseases associated with one or more of MLL1, MLL2, MLL fusion proteins, and menin.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 10, 2023
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, KURA ONCOLOGY, INC.
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Dmitry Borkin, Jonathan Pollock, Hongzhi Miao, Duxin Sun, Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu